Dr. Gonzalo Domingo named leader of PATH’s Diagnostics Program

PATH is pleased to announce the appointment of Dr. Gonzalo Domingo as director of PATH’s Diagnostic Program.

“Gonzalo brings extensive experience in leading and managing product development efforts from early concept development through every stage of the research and development process, including registration and introduction,” notes Melanie Saville, Chief Scientific Officer and leader of PATH’s Product Development Division. “I am delighted that he will take on this vital role at PATH.”

Dr. Domingo will lead our team of experts in diagnostic innovations, whose work has resulted in numerous diagnostic tools that have improved point of care evaluation and treatment in low-resource settings. The Diagnostics Program’s experience encompasses research and development of point-of-care tests and rapid diagnostic tests, as well as conducting product evaluation and down selection to inform which products will be best; their work includes developing reference standards and core reagents to advance the diagnostics field. The team’s breadth of expertise spans myriad infectious and other diseases and multiple platforms.

In particular, Dr. Domingo led PATH’s groundbreaking work in collaboration with partners world-wide to develop and commercialize the G6PD point-of-care tests for glucose-6-phosphate dehydrogenase deficiency to guide the treatment of patients with P. vivax malaria.

“Diagnostics are essential to fostering healthy communities – from pandemic preparedness and response to ensuring patients receive the most appropriate treatment, as quickly as possible,” commented Dr. Domingo. “I am honored and excited to lead this impressive group and work with partners to continue advancing urgently needed diagnostic solutions.”